Figure 6
Evaluation of the Bxl-xL/Bcl-2 inhibitor ABT-737 in a 3D cell culture approach. (a) H&E staining and IHC against Bcl-xL, Ki67 and cleaved PARP on scaffold sections, revealing a significant (P<0.001) amount of apoptotic HT29 cells in ABT-737 (1 μM for 4 days) treated samples (n=5 scaffolds per group). Scale bar indicates magnification for all panels. (b) Correlating quantification of Ki67- and cleaved PARP-positive cells, determined by counting, showing a significant increase (P<0.001) in dead cells (cleaved PARP) but no significant changes in the proliferative capacity (Ki67) under ABT-737 treatment (n=5 scaffolds per group). (c) Measurement of LDH in the supernatant of scaffolds after 4 days of treatment with the inhibitor (1 μM), showing a 1.9-fold higher concentration under treatment (P<0.001). Values are expressed as means+S.D. ***P<0.001
